| 洪岩,夏稻子,礼广森,王月爱.应用背向散射技术评价乳腺癌患者表阿霉素心脏毒性的价值崔[J].中国医学影像技术,2007,23(1):85~87 |
| 应用背向散射技术评价乳腺癌患者表阿霉素心脏毒性的价值崔 |
| Study on the Eprirubincin-induced cardiotoxity in breast cancer patients by integrated backscatterand |
| 投稿时间：2006-03-14 修订日期：2006-12-01 |
| DOI： |
| 中文关键词: 背向散射积分 表阿霉素 心脏毒性 超声心动描记术 |
| 英文关键词:Integrated backscatter Epirubicin Cardiotoxity Echocardiagraphy |
| 基金项目: |
|
| 摘要点击次数: 2014 |
| 全文下载次数: 983 |
| 中文摘要: |
| 目的 探讨超声背向散射(IBS)技术评价乳腺癌术后患者表阿霉素心脏毒性的价值。方法 133例乳腺癌患者分为3组:A组45例,给予表阿霉素总剂量180~240 mg/m2。B组48例,给予表阿霉素总剂量≥360 mg/m2。C组为对照组,40例,未给予化疗。取胸骨旁左室长轴切面,测量A、B两组化疗前后及C组左室后壁心内膜下及心外膜下、室间隔右室侧1/2及左室侧1/2心肌的平均背向散射积分(IBS)、随心动周期变化的背向散射积分幅度(CVIB),计算各层校正背向散射积分(IBS％)以及CVIB的跨壁梯度(TGCV)、CVIB的跨壁梯度指数(TGI)。结果 A组与C组、A组化疗前之间常规超声参数(LVDd、LVDs、IVSTd、LVEF、 FS、 E/A)及CVIB、IBS%、TGCV、TGI无显著性差异(P>0.05)。A组与B组间常规超声参数无显著性差异(P>0.05),B组与C组及B两组化疗前之间常规超声参数(E/A除外)无显著性差异(P>0.05)。B组参数E/A、CVIB、TGCV、TGI显著减低、IBS%显著升高,与A组、C组及B组化疗前之间有显著性差异(P<0.05或P<0.01)。结论 超声背向散射技术可作为早期评价乳腺癌术后患者表阿霉素心脏毒性的手段之一。 |
| 英文摘要: |
| Objective To investige the Eprirubincin-induced cardiotoxity in breast cancer patients by integrated backscatter. Methods One hundred and thirty-three breast cancer patients were divided into three groups: 45 patients in group A were given Epirubicin(Epi)of 180~240 mg/m2, 48 patients in group B were given Epirubicin of ≥360 mg/m2, and 40 patients after surging without chemotherapy in group C as the control group. The integrated backscatter (IBS), cyclic variation of integrated backscatter(CVIB)were examined IBS%, then TGCV(transmural gradient of CVIB), TGI(transmural gradient index of CVIB)were obtainedand.Results The conventional echographic parameters (such as LVDd, LVDs, IVSTd, LVEF, FS, E/A ) and CVIB, IBS%, TGCV, TGI were no significantce difference between group A and group C, so is it with A group before chemotherapy (P>0.05). The conventional echographic parameters were no significant difference between groups A and B (P>0.05). The conventional echographic parameters (E/A was not include)were no significant difference between group B and group C,so is it with group B before chemotherapy (P>0.05). The E/A and CVIB,TGCV,TGI were considerably lower, the IBS% was considerably higher in group B. They were significant difference between groups A and B, groups C and B, group A and group C,so is it with group B before chemotherapy (P<0.01 or P<0.05). Conclusion IBS may be valuable to assess the Eprirubincin-induced cardiotoxity in breast cancer patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
